Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 15.36B P/E - EPS this Y 24.80% Ern Qtrly Grth -
Income -204.15M Forward P/E -79.56 EPS next Y 107.10% 50D Avg Chg -7.00%
Sales 2.5B PEG -0.76 EPS past 5Y - 200D Avg Chg 29.00%
Dividend N/A Price/Book 5.03 EPS next 5Y 98.50% 52W High Chg -16.00%
Recommedations 1.60 Quick Ratio 1.91 Shares Outstanding 181.53M 52W Low Chg 191.00%
Insider Own 1.01% ROA -3.04% Shares Float 179.56M Beta 1.23
Inst Own 87.02% ROE -6.60% Shares Shorted/Prior 9.89M/6.52M Price 85.13
Gross Margin 73.83% Profit Margin -8.17% Avg. Volume 1,843,972 Target Price 90.76
Oper. Margin -11.94% Earnings Date May 8 Volume 4,593,022 Change -11.73%
About Exact Sciences Corporation

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Exact Sciences Corporation News
04/24/24 Exact Sciences (EXAS) Stock Drops Despite Market Gains: Important Facts to Note
04/24/24 Here’s Why Baron Health Care Fund Reduced Exact Sciences Corporation (EXAS)
04/22/24 Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings?
04/22/24 10 Best Performing Biotech ETFs in 2024
04/17/24 Why Exact Sciences (EXAS) Dipped More Than Broader Market Today
04/17/24 Exact Sciences Corporation's (NASDAQ:EXAS) Profit Outlook
04/15/24 Exact Sciences names Aaron Bloomer CFO
04/15/24 Exact Sciences Names Aaron Bloomer as New Chief Financial Officer
04/12/24 Here’s Why Exact Sciences Corporation (EXAS) Declined in Q1
04/11/24 Myriad Genetics (MYGN) Announces Favorable Research Results
04/11/24 Zacks Investment Ideas feature highlights: Exact Sciences, Kaiser Aluminum and Atmus Filtration Technologies
04/11/24 Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes
04/10/24 Exact Sciences (EXAS) Stock Moves -0.89%: What You Should Know
04/10/24 3 Buy-Rated Stocks Flexing Relative Strength
04/10/24 Search for Cancer Blood Test Continues Despite Illumina-Grail Deal’s Failure
04/09/24 ZTS, EXAS, AZN: Which Biotech Stock Is the Better Buy?
04/09/24 11 Best Biotech ETFs To Buy
04/08/24 Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024
04/08/24 Sorry, but Blood Tests Won’t Replace Stool Samples or Colonoscopies Yet
04/08/24 Exact Sciences Schedules First Quarter 2024 Earnings Call
EXAS Chatroom

User Image AlaskanMatt Posted - 10 hours ago

$EXAS Back in at 59 today.

User Image ManyThanks212 Posted - 13 hours ago

$EXAS whats all these damn forms lol

User Image bearcreekzeke Posted - 13 hours ago

$EXAS What in the Sam Hill is going on here? Any ideas? After 3 plus years of sell-off after sell-off after sell-off I am getting a bit perturbed. Never has so much good news been treated with such unrelenting selling. Sick and tired of being sick and tired!

User Image thingkfast Posted - 15 hours ago

$EXAS pricing in shield approval, bad ER? Idk

User Image crtlabz Posted - 18 hours ago

$EXAS laughable, almost!

User Image SW51 Posted - 19 hours ago

$EXAS ugh, 5 handle again....

User Image thingkfast Posted - 19 hours ago

$EXAS I don’t understand the volatile swings here but I do know earnings are going to be key

User Image Anecdotal Posted - 1 day ago

@bearcreekzeke UPOD! $EXAS That has consistently been their m.o.

User Image Ford150 Posted - 1 day ago

$EXAS a modest 600 share position here We are a big fan of this one

User Image Kleeno Posted - 1 day ago

$EXAS Should I go to the Dark Side??? LOL

User Image bearcreekzeke Posted - 1 day ago

$EXAS Since December of 2022, Cathie Wood's ARK funds have sold over 13 million shares of Exact Sciences. Down to just 2.75 million shares in $ARKK and $ARKG combined, after owning more than 16 million shares in December of 2022. Crazy buy high, sell low investment strategy, after touting long-term 5 year investment horizon. Nutty! The good news is that her negative, destructive influence on Exact Sciences shares is much, much less than it was previously. Will be thrilled to put her share ownership debacle in the rearview mirror!

User Image Willieberich Posted - 2 days ago

$EXAS I'll see you at 70 this week!!!

User Image Willieberich Posted - 2 days ago

$EXAS going up!!!

User Image WallStreetBuyDip Posted - 2 days ago

This is the track record showing the results for Small + Mid cap stocks from ONLY buying when H% is low Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself. Will next trade $EXAS + $RUN when H% is low for a reversal trade like I did for other small + mid cap stocks.

User Image bearcreekzeke Posted - 2 days ago

$EXAS CFO Jeff Elliott's last earnings call. I am sure he has no intention of going out on a sour note I am expecting more of his trademark under promise - over deliver. Hoping he has cranked up profitability metrics for this past quarter. Somewhat concerned about the flu season being pretty bad this year. Fingers crossed!

User Image Woodman7 Posted - 2 days ago

@SW51 - her selling may be creating an artificial damper on $EXAS . Buying opportunity??

User Image SW51 Posted - 2 days ago

$EXAS Cathie Wood’s ARK Funds Are Sinking Fast https://www.wsj.com/articles/ark-funds-cathie-wood-investors-56e2950c A fraud, as suspected

User Image WallStRider Posted - 3 days ago

$EXAS hey what’s 20 points keep buying lol Try reading a chart

User Image Woodman7 Posted - 3 days ago

@1Freebird - yes - esp colon cancer $EXAS $TDOC

User Image Anecdotal Posted - 3 days ago

@bearcreekzeke $EXAS I found more change. Buying.

User Image Willieberich Posted - 3 days ago

$EXAS buying more ! To many cathie wood haters out there ! This one is a buy..

User Image SW51 Posted - 3 days ago

$EXAS fade the mkt and exas

User Image WSAnalysis Posted - 3 days ago

Time to sell everything that has Cathie’s approval $DNA $TSLA $EXAS $KTOS $TDOC

User Image Woodman7 Posted - 4 days ago

$TDOC - oncology! I think $TDOC should have some type of strategic relationship with $EXAS. They could make a huge brand statement by embracing the goal of defeating cancer within their patient base. $EXAS is becoming a juggernaut in the non-invasive cancer screening space. $TDOC needs to take advantage and prescribe screening every three years to everyone over 45. Value added services in a critically important Heath area!

User Image Willieberich Posted - 5 days ago

$EXAS shorts are controlling the price action here ! On earnings beat and put some profit in there .and you will get rid of them and the price will jump to 80 .quickly. this kind of action is happening all over the stock market .it's not an investor market it's a trading market .so keep a kong and Starr trading with another account..

User Image Woodman7 Posted - 5 days ago

@clmclane - I def believe they have the best shot at it that’s for sure $EXAS

User Image Woodman7 Posted - 5 days ago

@SW51 - Thank you for your very insights, but I very respectfully disagree. WS is looking for all this growth to turn into profitability, which hasn’t happened yet. I am of the opinion this could be a watershed qtr financially where analysts can really start to see the scale benefit that is to come. I think 2Q ER is where additional pipeline type catalysts will carry the day. $EXAS

User Image clmclane Posted - 5 days ago

$EXAS I believe this company will figure out how to screen for cancer by a simple blood test and detect stage 1 and 2 instead of it being detected at stage 3 or 4.

User Image Woodman7 Posted - 6 days ago

$EXAS - 2 1/2 weeks until the 1Q ER. Whoever is selling this stock is going to be in for a shock when they overachieve against expected revenue. And, not by just a little.. Also, assuming I’m right, they will overachieve against EBITA as well, because they are right at the tipping point of scale in their screening business. Needless to say, I am very bullish on EXAS and believe this ER is going to be extremely positive. Not discouraged at all by recent price action. Just amazed that you can buy a first class franchise with such a bright future for this valuation.

User Image bearcreekzeke Posted - 6 days ago

$EXAS Maybe the article should be retitled? "Aaron Bloomer, CFO - The $2 Billion Dollar Mistake?" Read it here: https://www.reddit.com/r/exactsciences/comments/1c5vkvp/aaron_bloomer_cfo_the_billion_dollar_mistake/

Analyst Ratings
Citigroup Buy Apr 3, 24
Canaccord Genuity Buy Feb 22, 24
Benchmark Buy Jan 2, 24
Guggenheim Buy Dec 14, 23
Wolfe Research Outperform Dec 13, 23
Goldman Sachs Buy Nov 3, 23
Piper Sandler Overweight Oct 16, 23
Piper Sandler Overweight Oct 10, 23
Bernstein Outperform Sep 28, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Condella Sarah EVP, Human Resources EVP, Human Resources Jan 02 Sell 73.50 2,000 147,000 69,423 01/04/24
Baranick Brian Gen. Mgr., Precision.. Gen. Mgr., Precision Oncology Jan 02 Sell 73.50 879 64,606 7,992 01/04/24
Condella Sarah EVP, Human Resources EVP, Human Resources Dec 14 Sell 70.00 2,000 140,000 71,423 12/18/23
Cunningham Everett Chief Commercial Off.. Chief Commercial Officer Oct 11 Sell 66.49 13,007 864,835 37,909 10/13/23
Cunningham Everett Chief Commercial Off.. Chief Commercial Officer Oct 11 Option 0 27,504 50,916 10/13/23
Herriott James General Counsel General Counsel Feb 14 Sell 65.59 400 26,236 9,095 02/16/23
Herriott James General Counsel General Counsel Feb 14 Option 0 883 9,495 02/16/23
Condella Sarah EVP, Human Resources EVP, Human Resources Feb 14 Sell 65.59 954 62,573 85,166 02/16/23
Condella Sarah EVP, Human Resources EVP, Human Resources Feb 14 Option 0 2,030 86,120 02/16/23
ORVILLE JACOB A General Manager, Scr.. General Manager, Screening Feb 14 Sell 69.59 954 66,389 16,114 02/16/23
ORVILLE JACOB A General Manager, Scr.. General Manager, Screening Feb 14 Option 0 2,030 17,068 02/16/23
Cunningham Everett Chief Commercial Off.. Chief Commercial Officer Oct 11 Sell 31.37 16,872 529,275 18,654 10/13/22
Cunningham Everett Chief Commercial Off.. Chief Commercial Officer Oct 11 Option 0 35,006 35,526 10/13/22
Zanotti Katherine S Director Director Jun 30 Sell 40.13 1,086 43,581 60,318 07/01/22
Doyle James Edward Director Director Jun 07 Option 16.52 3,000 49,560 42,830 06/08/22
Doyle James Edward Director Director Mar 17 Option 16.52 10,000 165,200 39,830 03/18/22
Conroy Kevin T President and CEO President and CEO Mar 17 Option 23.92 236,622 5,659,998 1,167,606 03/18/22
Conroy Kevin T President and CEO President and CEO Feb 28 Option 0 29,887 945,283 03/02/22
Conroy Kevin T President and CEO President and CEO Feb 28 Sell 76.69 14,299 1,096,590 930,984 03/02/22
COWARD D SCOTT Chief Legal Officer Chief Legal Officer Feb 28 Option 0 8,288 20,146 03/02/22
COWARD D SCOTT Chief Legal Officer Chief Legal Officer Feb 28 Sell 76.69 3,912 300,011 16,234 03/02/22
Elliott Jeffrey Thomas Chief Financial Offi.. Chief Financial Officer Feb 28 Option 0 8,462 23,178 03/02/22
Elliott Jeffrey Thomas Chief Financial Offi.. Chief Financial Officer Feb 28 Sell 76.69 4,050 310,594 19,128 03/02/22
Condella Sarah SVP, Human Resources SVP, Human Resources Feb 23 Option 0 10,197 92,894 02/25/22
Condella Sarah SVP, Human Resources SVP, Human Resources Feb 23 Sell 70.1 4,717 330,662 88,177 02/25/22
Conroy Kevin T President and CEO President and CEO Feb 23 Option 0 58,643 942,522 02/25/22
Conroy Kevin T President and CEO President and CEO Feb 23 Sell 70.1 27,126 1,901,533 915,396 02/25/22
COWARD D SCOTT Chief Administrative.. Chief Administrative Officer Feb 23 Option 0 12,747 17,673 02/25/22
COWARD D SCOTT Chief Administrative.. Chief Administrative Officer Feb 23 Sell 70.1 5,815 407,631 11,858 02/25/22
Elliott Jeffrey Thomas Chief Financial Offi.. Chief Financial Officer Feb 23 Option 0 12,747 20,613 02/25/22
Elliott Jeffrey Thomas Chief Financial Offi.. Chief Financial Officer Feb 23 Sell 70.1 5,897 413,380 14,716 02/25/22
ORVILLE JACOB A General Manager, New.. General Manager, New Ventures Feb 23 Option 0 10,197 19,754 02/25/22
ORVILLE JACOB A General Manager, New.. General Manager, New Ventures Feb 23 Sell 70.1 4,717 330,662 15,037 02/25/22
Elliott Jeffrey Thomas Chief Financial Offi.. Chief Financial Officer Feb 22 Option 0 3,112 9,423 02/24/22
Elliott Jeffrey Thomas Chief Financial Offi.. Chief Financial Officer Feb 22 Sell 69.05 1,557 107,511 7,866 02/24/22
Condella Sarah SVP, Human Resources SVP, Human Resources Feb 22 Option 0 2,247 83,821 02/24/22
Condella Sarah SVP, Human Resources SVP, Human Resources Feb 22 Sell 69.05 1,124 77,612 82,697 02/24/22
Conroy Kevin T President and CEO President and CEO Feb 22 Sell 69.05 5,188 358,231 883,879 02/24/22
Conroy Kevin T President and CEO President and CEO Feb 22 Option 0 10,373 889,067 02/24/22
ORVILLE JACOB A General Manager, New.. General Manager, New Ventures Feb 22 Option 0 2,247 10,682 02/24/22
ORVILLE JACOB A General Manager, New.. General Manager, New Ventures Feb 22 Sell 69.05 1,125 77,681 9,557 02/24/22
COWARD D SCOTT Chief Administrative.. Chief Administrative Officer Feb 22 Option 0 2,247 6,035 02/24/22
COWARD D SCOTT Chief Administrative.. Chief Administrative Officer Feb 22 Sell 69.05 1,109 76,576 4,926 02/24/22
Condella Sarah SVP, Human Resources SVP, Human Resources Feb 14 Option 78.33 2,030 159,010 82,512 02/16/22
Condella Sarah SVP, Human Resources SVP, Human Resources Feb 14 Sell 79.55 938 74,618 81,574 02/16/22
Elliott Jeffrey Thomas Chief Financial Offi.. Chief Financial Officer Feb 14 Option 78.33 3,972 311,127 8,150 02/16/22
Elliott Jeffrey Thomas Chief Financial Offi.. Chief Financial Officer Feb 14 Sell 79.55 1,839 146,292 6,311 02/16/22
Conroy Kevin T President and CEO President and CEO Feb 14 Option 32.74 222,316 7,278,626 893,103 02/16/22
Conroy Kevin T President and CEO President and CEO Feb 14 Sell 79.55 14,409 1,146,236 878,694 02/16/22
ORVILLE JACOB A General Manager, New.. General Manager, New Ventures Feb 14 Option 78.33 2,030 159,010 7,475 02/16/22